Cellectis S.A.

ALCLS

FR0010425595

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 11:55:00 2025-07-10 am EDT			5-day change	1st Jan Change
1.332 ^EUR	-0.60%		-1.77%	-18.28%

Jul. 09	European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading	MT
Jul. 08	European Equities Traded in the US as American Depositary Receipts Advance in Tuesday Trading	MT

European Equities Traded in the US as American Depositary Receipts Advance Wednesday

Published on 06/04/2025 at 11:19

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Cellectis S.A.

European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading	Jul. 09	MT
European Equities Traded in the US as American Depositary Receipts Advance in Tuesday Trading	Jul. 08	MT
European Equities Traded in the US as American Depositary Receipts Lower in Monday Trading	Jul. 07	MT
European Equities Traded in the US as American Depositary Receipts Track Lower in Thursday Trading	Jul. 03	MT
Cellectis Proposes $200 Million Mixed Shelf Offering	Jul. 02	MT
European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading	Jul. 02	MT
European Equities Traded in the US as American Depositary Receipts Edge Higher in Tuesday Trading	Jul. 01	MT
Cellectis S.A. Announces Board Changes	Jun. 26	CI
European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading	Jun. 26	MT
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading	Jun. 24	MT
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	Jun. 16	MT
European Equities Traded in the US as American Depositary Receipts Slide Friday	Jun. 13	MT
European Equities Traded in the US as American Depositary Receipts Advance Wednesday	Jun. 04	MT
European Equities Traded in the US as American Depositary Receipts Modestly Higher in Thursday Trading	May. 29	MT
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading; End Week Lower	May. 23	MT
Cellectis S.A. Announces Resignation of Pierre Bastid from the Board of Directors, Effective June 26, 2025	May. 21	CI
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading	May. 20	MT
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading	May. 19	MT
European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading; Up 1.4% for Week	May. 16	MT
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	May. 15	MT
European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading	May. 13	MT
Cellectis S.A. Reports Earnings Results for the First Quarter Ended March 31, 2025	May. 12	CI
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	May. 12	MT
European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading	May. 07	MT
European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading	May. 06	MT

Cellectis S.A. is a clinical-stage biotechnology company using its pioneering TALEN® genome-editing technology to develop innovative therapies for the treatment of serious diseases. Cellectis S.A. is developing the first CAR T cell-based allogeneic immunotherapy therapeutics, inventing the concept of off-the-shelf, ready-to-use engineered CAR T cells for the treatment of cancer patients, and a platform for for the development of gene therapies in other therapeutic indications. Thanks to its fully in-house production capabilities, Cellectis S.A. is one of the few genome-editing companies to control the cell and gene therapy value chain from end to end.

Employees

219

Sector

Biotechnology & Medical Research

Calendar

Jul. 14 - Cell Therapies Process Development Summit

More about the company